Vascular Endothelial Growth Factor Inhibitor
WHO Essential Medicine EML section: Anti-vascular endothelial growth factor (VEGF) preparations
This is information only, not a prescription. Talk to a doctor or pharmacist before taking any medicine. For an overdose or poisoning, call 102.
Bevacizumab is used for: is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. It belongs to the class: Vascular Endothelial Growth Factor Inhibitor. Common side effects include: The following clinically significant adverse reactions are described elsewhere in the labeling: Gastrointestinal Perforations and Fistulae.. Vascular Endothelial Growth Factor Inhibitor. What it is used for: is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. generated by SI from cited sources · general information, not a diagnosis · consult a health professional
Sources: FDA SPL label (openFDA/DailyMed); RxNorm (NLM) · Reference · Reference · Reference
Nepal brand names not included: no licence-safe source.
is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
Bevacizumab products bind VEGF and prevent the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis.
The following clinically significant adverse reactions are described elsewhere in the labeling: Gastrointestinal Perforations and Fistulae. Surgery and Wound Healing Complications. Hemorrhage. Arterial Thromboembolic Events. Venous Thromboembolic Events. Hypertension. Posterior Reversible Encephalopathy Syndrome.
None. None
Pregnancy (label summary): Risk Summary Based on findings from animal studies and their mechanism of action, bevacizumab products may cause fetal harm in pregnant women.
For a suspected overdose or poisoning, call 102 now and go to the nearest emergency hospital.
Call 102What is Bevacizumab used for?
is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
How does Bevacizumab work?
Bevacizumab products bind VEGF and prevent the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis.
What are the side effects of Bevacizumab?
The following clinically significant adverse reactions are described elsewhere in the labeling: Gastrointestinal Perforations and Fistulae. Surgery and Wound Healing Complications. Hemorrhage. Arterial Thromboembolic Events. Venous Thromboembolic Events. Hypertension.
Who should not take Bevacizumab?
None. None
Can I take Bevacizumab in pregnancy or while breastfeeding?
Pregnancy (label summary): Risk Summary Based on findings from animal studies and their mechanism of action, bevacizumab products may cause fetal harm in pregnant women.
What is the dose of Bevacizumab?
Not provided here. Ask a doctor or pharmacist.
What is Bevacizumab?
Bevacizumab is used for: is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. It belongs to the class: Vascular Endothelial Growth Factor Inhibitor. Common s…
Sources: FDA SPL label (openFDA/DailyMed); RxNorm (NLM) · Reference · Reference · Reference
US FDA DailyMed; NLM RxNorm